한국어
English
日本語
中文(简体)
SPECT Capsule 200 mg (Rade tyrosine hydrochloride)
213.6mg
Hard capsule · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Ruxolitinib hydrochloride is an anticancer agent used in the treatment of chronic myeloid leukemia.
MFDS ingredient code M253750
Ruxolitinib hydrochloride is an anticancer agent in the class of tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia. This ingredient is included in medications for the purpose of inhibiting the growth and division of cancer cells.
Ruxolitinib hydrochloride blocks the activity of a specific enzyme inside cancer cells called tyrosine kinase, preventing the signaling that allows cancer cells to proliferate. As a result, the growth of cancer cells is inhibited and apoptosis is promoted.
Approved uses differ by product. Check each product's information for its actual use.
Ruxolitinib hydrochloride is effective against specific mutations compared to other tyrosine kinase inhibitors and is differentiated in terms of side effect profile and drug interactions. This plays an important role in patient-specific therapy.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
